Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 86

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 86
---
 macrophages and neutrophils, potentially 
 improving intracellular antibiotic delivery and bactericidal activity [4].                       |

| - | No                                                                                       
 Cross-Resistance                                                                         
 Due to its unique mechanism, mupirocin does not display cross-resistance with β-lactams, 
 glycopeptides, or other classes of antibiotics, making it valuable in treating resistant 
 strains [2].                                                                             |

| - | Preclinical                                                                                     
 Safety Profile: nano-mupirocin formulations have shown favorable safety profiles in preclinical 
 studies, with no significant adverse effects reported [3].                                      |

| - | WHO                                                                                      
 Priority Pathogens: The World Health Organization (WHO) lists MRSA, VRE, and Neisseria   
 gonorrhoeae among its high-priority pathogens due to increasing antimicrobial resistance 
 [5]. Mupirocin’s demonstrated activity against these bacteria supports its potential     
 relevance in global health initiatives.                                                  |

| - | Proof                                                                                            
 of concept obtained in reputable NIH laboratories in the US. A team of researchers from          
 the National Institute of Health in collaboration with Prof. Barenholtz’s team have              
 demonstrated proof of concept in a number of preclinical studies performed on resistant bacteria 
 which causes severe life-threating infections including necrotizing fasciitis, endocarditis,     
 and gonorrhea. A few in vitro and in vivo studies testing novel LNP mupirocin                    
 were supported and conducted in collaboration with the National Institute of Health/National     
 Institute of Allergy and Infectious Diseases (NIH/NIAID). The results were published in the      
 Antimicrobial Agents and Chemotherapy journal [6] as well as in the Journal of Controlled        
 Release [7].                                                                                     |

Based on the above mentioned research
results we believe our novel formulation of Mupirocin has significant potential in treating life threatening human diseases originating
from resistant bacteria.

References

| 1. | Williams JD. Antibacterial                                                                
 activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrobial 
 Agents and Chemotherapy. 1985;27(4):495–498. DOI: 10.1128/aac.27.4.495                    |

| 2. | DrugBank Online:                                                     
 Mupirocin (DB00410). DrugBank. https://go.drugbank.com/drugs/DB00410 |

| 3. | Kulkarni NS, et                                                                                   
 al